FOS and metabolic dysfunction-associated steatotic liver disease: Given the wide range of pathways altered by c‐Fos, we compared the 2 and 4 months ORA results with pathways implicated in the development and progression stages of MASLD.[18] Overlapping pathways, such as PPAR and PI3K‐Akt signaling, associated with development and progression stages of MASLD and FosHep are indicated in Venn diagram (Figure 6H).